Business Wire

CA-USERTESTING

13.7.2022 15:02:08 CEST | Business Wire | Press release

Share
UserTesting Enhances Its Machine Learning-Powered Post-Test Analysis and Redesigns Its Platform Experience for Improved Team Collaboration

UserTesting (NYSE: USER), a leader in video-based human insight , today announced advanced Instant Insight features, powered by machine learning, to help companies expedite the analysis of human insights at the test-level and accelerate time to insights. Using data-automation and proprietary models, the UserTestingⓇ Human Insight Platform can detect patterns and anomalies in the customer data, and automatically surface high-value insights within the Customer Experience Narratives. The latest product updates are designed to help companies uncover key customer perspectives more quickly, so team members can understand where to focus their efforts for greater success. In addition to English and German, UserTesting is now available in French, and customers can test in the French language with access to French speaking contributors.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220713005310/en/

New features in this product release:

Discover Patterns and Key Customer Takeaways More Quickly with Test-Level Instant Insights
UserTesting’s test-level Instant Insight feature utilizes data-driven automation and machine learning models to accelerate post-test analysis by automatically detecting patterns, anomalies, and key insights within customer data across multiple tasks and sessions. Customers can quickly identify important takeaways from their tests while alleviating the burden of lengthy post-test analysis.

Intuitively Navigate and Collaborate with UserTesting
UserTesting’s navigation redesign enables customers to access core functionalities more readily, with a new user interface, folder management, easily accessible resources, and a workspace switcher. Updates make the testing and insight management process more intuitive and accessible for broader team use, enabling scalability for growing teams across organizations. Additionally, IT departments can now manage team access more seamlessly with self-service, single sign-on, providing more governance for enterprise-scale deployments.

A Redesigned Card Sorting Experience
UserTesting has enhanced its card sorting capabilities within the UserTesting Human Insight Platform so users can view video feedback alongside card sorting metrics and gather a complete understanding of contributors’ mental models with this streamlined solution. Companies can build navigation or sitemaps based on customer expectations and behaviors, and describe categories to drive better engagement. This helps companies save costs and adapt to rapidly changing customer needs, or changes to their respective businesses, with timely feedback of how digital properties are organized and used.

En français … UserTesting
UserTesting is now available in French for both customer and contributor experiences. Companies looking to get feedback from French-speaking consumers can now do so with the UserTesting Human Insight Platform, as tests can be conducted in French, with French-speaking contributors, giving organizations the ability to target and connect with more people around the world.

Now Supports Native Video/Audio Testing
For companies wanting to test sensitive media content with greater efficiency, UserTesting enables customers to securely upload audio, video, and other media assets directly onto the Human Insight Platform with its new native media asset testing feature. Companies can gather contributor feedback easily on unreleased assets, like video and audio files, before launching them to the public.

“More than ever, it’s imperative that companies know how their customers feel, and why. UserTesting is continuously innovating its platform to help companies gain actionable insights so they can make smarter and faster business decisions,” said Kaj van de Loo, CTO at UserTesting. “UserTesting’s data-driven automation helps customers speed up analysis of video feedback, so they can make decisions quicker than ever. The platform helps companies optimize the use of human insights, so that they can better understand what is driving customer behavior, and adapt to any changes in the market.”

UserTesting will be hosting a webinar highlighting its latest product release on August 3 at 11:00 a.m. PT/2:00 p.m. ET. Register for the webinar here .

About UserTesting
UserTesting (NYSE: USER) has fundamentally changed the way organizations get insights from customers with fast, opt-in feedback and experience capture technology. The UserTesting Human Insight Platform taps into our global network of real people and generates video-based recorded experiences, so anyone in an organization can directly ask questions, hear what users say, see what they mean, and understand what it’s actually like to be a customer. Unlike approaches that track user behavior then try to infer what that behavior means, UserTesting reduces guesswork and brings customer experience data to life with human insight. UserTesting has approximately 2,500 customers, including more than half of the world’s top 100 most valuable brands according to Forbes. UserTesting is headquartered in San Francisco, California. To learn more, visit www.usertesting.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye